Compare Abeona Therapeutics Inc (ABEO) vs Blackstone Inc (BX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Blackstone Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Blackstone Inc trades at $117.91 (market cap $147.67B). The key difference: Blackstone Inc is far larger — about 395.6× Abeona Therapeutics Inc's market cap, and Blackstone Inc pays a 4.11% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BX | |
|---|---|---|
Market Cap | $373.32M | $147.67B |
Sector | Health | Financials |
52-Week High | $7.23 | $188.68 |
52-Week Low | $4.17 | $102.12 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 4.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BX trades at $120.88, down 1.51% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $12.41B in 2025, with a net income margin of 24.27% and robust ROE of 37.36%. Recent news highlights strategic moves in energy transition, AI data centers, and credit markets, including a $30B Japan AI investment plan reported by Reuters on June 23, 2026.
Outlook remains positive with a consensus price target of $150.78, implying 25% upside, supported by 62% analyst buy ratings. Risks include execution of large investments and market volatility, but fundamentals and institutional sentiment favor long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
